

Louisiana Administrative Code**Title 46 – Professional and Occupational Standards****Part LIII – Pharmacists****Chapter 29. Prescription Monitoring Program****§2901. Definitions**

- A. As used in this Chapter, the following terms shall have the meaning ascribed to them unless the context clearly indicates otherwise:

* * *

Drugs of Concern – drugs other than controlled substances as defined by rule whose use requires tracking for public health purposes or which demonstrate a potential for abuse, including any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, ethers, isomers, and salts of isomers [whenever the existence of such salts, esters, ethers, isomers, and salts of isomers is possible within the specific chemical designation]:

- a. butalbital when in combination with at least 325 milligrams of acetaminophen per dosage unit.
- b. naloxone.
- c. elbasvir / grazoprevir.
- d. glecaprevir / pibrentasvir.
- e. ledipasvir / sofosbuvir.
- f. ombitasvir / paretaprevir / ritonavir / dasabuvir.
- g. sofosbuvir.
- h. sofosbuvir / velpatasvir.
- i. sofosbuvir / velpatasvir / voxilaprevir.
- j. gabapentin.
- k. promethazine in oral liquid formulations.

* * *

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1345 (July 2007), amended LR 36:755 (April 2010), effective September 1, 2010, amended LR 39:314 (February 2013), amended LR 40:1096 (June 2014), amended LR 41:684 (April 2015), amended by the Department of Health, Board of Pharmacy, LR 45:42 (January 2019), amended LR